Sugi Predict

Sugi Predict / Targets / DYRK3

DYRK3

Dual specificity tyrosine-phosphorylation-regulated kinase 3 · O43781 · DYRK3 on Sugi Atlas →

72,223 patent compounds predicted against DYRK3, 52,560 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL102235 SCHEMBL102235 1.00 16/20
SCHEMBL102656 SCHEMBL102656 0.79 16/20
SCHEMBL102951 SCHEMBL102951 0.76 16/20
SCHEMBL102660 SCHEMBL102660 0.75 16/20
SCHEMBL102233 SCHEMBL102233 1.00 15/20
SCHEMBL103266 SCHEMBL103266 0.85 15/20
SCHEMBL102955 SCHEMBL102955 0.78 15/20
SCHEMBL102650 SCHEMBL102650 0.76 15/20
SCHEMBL102239 SCHEMBL102239 0.70 14/20
SCHEMBL102236 SCHEMBL102236 0.71 13/20
SCHEMBL102764 SCHEMBL102764 0.71 13/20
SCHEMBL102507 SCHEMBL102507 0.78 12/20
SCHEMBL102984 SCHEMBL102984 0.77 12/20
SCHEMBL102952 SCHEMBL102952 0.76 12/20
SCHEMBL102225 SCHEMBL102225 0.72 12/20
SCHEMBL102240 SCHEMBL102240 0.67 12/20
SCHEMBL103262 SCHEMBL103262 0.67 12/20
SCHEMBL102942 SCHEMBL102942 1.00 11/20
SCHEMBL103265 SCHEMBL103265 1.00 11/20
SCHEMBL102940 SCHEMBL102940 0.78 11/20

Clinical trials — most relevant to DYRK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer PHASE4RECRUITING
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes nanUNKNOWN
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DYRK3 binder may also engage these)

ProteinNameSimilarity
Q922Y0 — 1.000 Q922Y0 →
Q4R6S5 — 1.000 Q4R6S5 →
Q4V8A3 — 1.000 Q4V8A3 →
DYRK4 Dual specificity tyrosine-phosphorylation-regulated kinase 4 0.994 landscape →
Q5XIT0 — 0.993 Q5XIT0 →
Q9TTK0 — 0.993 Q9TTK0 →
Q63553 — 0.993 Q63553 →
Q9JKV2 — 0.993 Q9JKV2 →
Q501Q9 — 0.993 Q501Q9 →
Q5SN53 — 0.992 Q5SN53 →
Q8VZD5 — 0.992 Q8VZD5 →
Q5U4C9 — 0.992 Q5U4C9 →
Q8BI55 — 0.992 Q8BI55 →
Q2NL51 — 0.991 Q2NL51 →
P51138 — 0.991 P51138 →
Q96287 — 0.991 Q96287 →
Q9Z188 — 0.991 Q9Z188 →
Q5R754 — 0.991 Q5R754 →
Q5ZIU3 — 0.991 Q5ZIU3 →
SNRK SNF-related serine/threonine-protein kinase 0.991 landscape →
DYRK2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 0.991 landscape →
P43294 — 0.991 P43294 →
Q9LV37 — 0.991 Q9LV37 →
O04160 — 0.991 O04160 →
P20793 — 0.990 P20793 →
O35831 — 0.990 O35831 →
GSK3B Glycogen synthase kinase-3 beta 0.990 landscape →
Q5YJC2 — 0.990 Q5YJC2 →
KAT6B Histone acetyltransferase KAT6B 0.990 landscape →
MAK Serine/threonine-protein kinase MAK 0.990 landscape →